Abstract
Get full access to this article
View all access options for this article.
References
1.
N.M.
Level
, “High Drug Costs Outweigh ‘Medicare for All’ as Top Health-care Issue for Voters,” LA Times , available at <https://www.latimes.com/politics/story/2020-01-21/high-cost-prescription-drugs-campaign-issue> (last visited February 27, 2020 ).
2.
A.S.
Kesselheim
,
J.
Avorn
, and
A.
Sarpatwari
“The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform,” JAMA 316 , no. 8 (2016 ): 858 -871 .
3.
N.E.
Wineinger
,
Y.
Zhang
, and
E.J.
Topol
“Trends in Prices of Popular Brand-Name Prescription Drugs in the United States,” JAMA Network Open 2 , no. 5 (2019 ): e194791 .
4.Global oncology trends 2019, IQVIA Institute for Human Data Science , available at <https://www.iqvia.com/insights/the-iqvia-institute/reports/global-oncology-trends-2019> (last visited February 27, 2020 ).
5.Pharmaceutical company drug sales as compared to R&D outlays , Knowledge Ecology International , available at <http://drugdatabase.info/pharmaceutical-company-drug-sales-as-compared-to-rd-outlays/> (last visited February 27, 2020 ).
6.
C.E.
Galkina
,
J.M.
Beierlein
,
N.S.
Khanuja
,
L.M.
McNamee
, and
F.D.
Ledley
“Contribution of NIH Funding to New Drug Approvals 2010-2016,” Proceedings of the National Academy of Sciences of the USA 115 , no. 10 (2018 ): 2329 -2334 .
7.
J.
Kaiser
, “Texas Voters Approve Second Life for State Cancer Funding Agency,” Science , available at <https://www.sciencemag.org/news/2019/11/texas-voters-approve-second-life-state-cancer-funding-agency> (last visited February 27, 2020 ).
8.
R.
Nayak
,
J.
Avorn
, and
A.S.
Kesselheim
“Public Sector Financial Support for Late Stage Discovery of New Drugs in the United States: Cohort Study,” BMJ 367 (2019 ): l5766 .
9.
A.
Sarpatwari
,
A.K.
LaPidus
, and
A.S.
Kesselheim
“Revisiting the National Institutes of Health Fair Pricing Condition: Promoting Drugs Developed with Government Support,” Annals of Internal Medicine (2020 )(E-pub ahead of print).
10.
A.S.
Kesselheim
,
J.
Avorn
, and
A.
Sarpatwari
“The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform,” JAMA 316 , no. 8 (2016 ): 858 -871 .
11.
A.
Swanson
, “Big Pharmaceutical Companies are Spending Far More on Marketing than Research,” Washington Post , available at <https://www.washingtonpost.com/news/wonk/wp/2015/02/11/big-pharmaceutical-companies-are-spending-far-more-on-marketing-than-research> (last visited February 27, 2020 ).
12.
W.
Lazonick
,
M.
Hopkins
,
K.
Jacobson
,
M.E.
Sakinç
, and
O.
Tulum
“US Pharma's Financialized Business Model,” Institute for New Economic Thinking , available at <https://www.ineteconomics.org/uploads/papers/Final-WP_60-Lazonick-et-al.-USPharma-Business-Model-sept-8.pdf> (last visited February 27, 2020 ).
13.
A.
Kaltenboeck
,
M.
Calsyn
,
G.W.J.
Frederix
,et al ., “Grounding Value-Based Drug Pricing in Population Health,” Clinical Pharmacology & Therapeutics (2020 ) (E-pub ahead of print).
14.
A.
Dunn
, “Amgen Exists Neuroscience R&D as Pharma Pulls Back from Field,” BioPharma Dive , available at <https://www.biopharmadive.com/news/amgen-exits-neuroscience-rd-as-pharma-pulls-back-from-field/566157/> (last visited March 13, 2020 ).
15.World Health Organization , “Lack of New Antibiotics Threatens Global Efforts to Contain Drug-Resistant Infections,” available at <https://www.who.int/news-room/detail/17-01-2020-17-01-2020-lack-of-new-antibiotics-threatens-global-efforts-to-contain-drug-resistant-infections> (last visited February 27, 2020 ).
16.World Health Organization , 2019 Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline , available at <https://apps.who.int/iris/bitstream/handle/10665/330420/9789240000193-eng.pdf> (last visited February 27, 2020 ).
17.
D.
Baker
, “The Future of the Pharmaceutical Industry: Beyond Government-Granted Monopolies,” CEPR , available at <http://cepr.net/images//stories/reports/pharma-industry-2019-03.pdf> (last visited February 27, 2020 ).
18.“Savings Available under Full Generic Substitution of Multiple Source Brand Drugs in Medicare Part D,” U.S. Department of Health and Human Services , available at <https://aspe.hhs.gov/system/files/pdf/259326/DP-Multisource-Brands-in-Part-D.pdf?utm_source=newsletter&utm_medium=email&utmcampaign=newsletter_axiosvitals&stream=top> (last visited February 27, 2020 ).
19.
M.
Mazzucato
, The Entrepreneurial State: Debunking Public vs. Private Sector Myths (New York, NY : Public Affairs ; 2015 ).